NCT02598817View on ClinicalTrials.gov

Acceptability and Gastrointestinal Tolerance of a High-Sn-2 Infant Formula

CompletedOBSERVATIONAL
Enrollment

276

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

January 8, 2020

Study Completion Date

January 5, 2021

Conditions
Infant Term Birth
Interventions
OTHER

Standard Infant Formula

Standard Infant Formula containing High Sn-2

Trial Locations (5)

Unknown

Tadawi General Hospital, Dammam

Almana Hospital, Jubail

Al Mouasat Hospital, Riyadh

Sheikh Khalifa Medical City, Abu Dhabi

Al Garhoud Private Hospital, Dubai

All Listed Sponsors
lead

Société des Produits Nestlé (SPN)

INDUSTRY

NCT02598817 - Acceptability and Gastrointestinal Tolerance of a High-Sn-2 Infant Formula | Biotech Hunter | Biotech Hunter